OR WAIT null SECS
The new location is the first step in the company’s plan to invest in the North American market over the next two years.
Bora Pharmaceuticals, a contract development and manufacturing organization (CDMO) based in Taiwan and specializing in complex modified-release products and solvent production, announced the opening of its first North American office in Delaware.
This is the first step in the company’s plan to invest in the North American market over the next two years, according to an Oct. 21, 2019 press release.
“Opening an office on the East coast of the [United States,] is a significant milestone for our organization and signals our continued commitment to the region,” said Bobby Sheng, CEO at Bora, in the press release. “The office is one phase of our expansion plans, as we continue to explore acquisition opportunities in the market. It will not only support our own future growth strategy but also allows us to better support our growing client base, as companies across the US continue to outsource their most complex oral solid dose projects to Bora.”
Louis Weber, Halo Pharma’s former senior director of business development, will serve as the company’s US managing director of business development and will maintain the growth strategy for the US and Europe, according to the release.
“As an industry, we are seeing a rising demand for large scale manufacturing projects that have the same diverse and challenging requirements of niche drug products. This is what attracted me to Bora, as its sweet spot is providing complex dosage forms on a large commercial scale,” Weber said. “I am eager to build an ambitious team in North America that is inspired to continue delivering smart, solution-driven support for our clients and their complex MR [modified release] projects.”
Bora will be exhibiting at CPhI Worldwide at stand 80B50 alongside the Taiwan Pharmaceutical Alliance from Nov. 5–7, 2019 in Frankfurt, Germany.